

# Granules India

Estimate change

TP change

Rating change



Bloomberg	GRAN IN
Equity Shares (m)	243
M.Cap.(INRb)/(USD\$)	126.7 / 1.5
52-Week Range (INR)	725 / 401
1, 6, 12 Rel. Per (%)	11/-14/12
12M Avg Val (INR M)	1407

## Financials & Valuations (INR b)

Y/E MARCH	FY25	FY26E	FY27E
Sales	44.8	50.6	58.7
EBITDA	9.5	11.3	13.5
Adj. PAT	4.8	5.9	7.6
EBIT Margin (%)	16.1	17.2	18.3
Cons. Adj. EPS (INR)	19.7	24.3	31.3
EPS Gr. (%)	13.6	23.3	28.9
BV/Sh. (INR)	153.2	176.3	206.5

## Ratios

Net D:E	0.4	0.3	0.3
RoE (%)	13.8	14.7	16.4
RoCE (%)	11.5	12.5	14.0
Payout (%)	5.7	4.8	3.7

## Valuations

P/E (x)	29.4	23.9	18.5
EV/EBITDA (x)	18.4	15.6	13.0
Div. Yield (%)	0.2	0.2	0.2
FCF Yield (%)	1.0	0.2	0.7
EV/Sales (x)	3.9	3.5	3.0

## Shareholding Pattern (%)

As On	Mar-25	Dec-24	Mar-24
Promoter	38.8	38.8	42.0
DII	22.4	19.6	10.7
FII	15.2	15.9	19.6
Others	23.6	25.7	27.8

FII includes depository receipts

**CMP: INR522**

**TP: INR600 (+15%)**

**Buy**

## Broadly in-line quarter; margin resilience led by FDF

### Gagillapur remediation, Senn integration weigh on near-term profitability

- Granules India (GRAN) delivered a slightly better-than-expected revenue in 4QFY25. However, it reported largely in-line EBITDA/PAT for the quarter.
- GRAN achieved the highest-ever gross margin on a quarterly basis, fueled by a strategic shift of product mix towards finished dosage formulation (FDF).
- Geography-wise, GRAN has garnered consistent growth in the North America segment, forming 77% of total sales for FY25.
- GRAN continues to work on product pipelines for other geographies such as the EU, LATAM, India, and the ROW markets.
- We cut our earnings estimates by 8%/6% for FY26/FY27 factoring in 1) an extended production disruption at the Gagillapur site to implement remediation measures, 2) additional operational costs related to Senn Chemicals, and 3) a weak pricing in Paracetamol API. We value GRAN at 18x 12M forward earnings to arrive at our TP of INR600.
- GRAN is focusing on building a differentiated product pipeline in the oncology and ADHD domains. With the Senn Chemicals acquisition, it is adding peptide CDMO as a growth driver for the future. It is also adding capacities in the FDF segment to cater to future manufacturing requirements. Overall, we expect a 14%/20%/26% revenue/EBITDA/PAT CAGR during FY25-27. **Reiterate BUY.**

### Segmental mix benefit offset by higher opex on a YoY basis

- GRAN's 4QFY25 sales grew 1.8% YoY to INR11.9b (our est. of INR11.3b), led by increased sales in the FDF segment.
- FDF sales grew 7% YoY to INR9.2b (77% of sales).
- API sales declined 9% YoY to INR1.4b (13% of sales).
- Intermediate (PFI) sales declined 17% YoY to INR1.2b (10% of sales).
- Gross margin (GM) expanded 330bp to 63.4% due to a change in the segmental mix and lower RM costs.
- However, the EBITDA margin dipped 60bp YoY to 21.1% (our est. of 22.3%) due to higher employee costs/other expenses (up 120bp/270bp as % of sales).
- EBITDA was flat YoY at INR2.5b (our est. of INR2.5b) for the quarter.
- During the quarter, GRAN received an insurance claim (INR307m) for business disruption due to an incident related to information security.
- Adjusted PAT was stable YoY to INR1.2b (our estimate: INR1.2b).
- In FY25, GRAN's revenue was flat YoY at INR44.8b, while EBITDA/PAT grew 7.8%/11.9% YoY to INR9.4b/INR4.7b.

### Highlights from the management commentary

- The ongoing remediation measures at the Gagillapur facility to resolve the USFDA regulatory issue are likely to impact production for a couple of more quarters.
- GRAN is awaiting USFDA/EU inspection at the Genome Valley Phase I plant. It started the Phase II plant and commenced validation activities recently.
- In addition to the amount spent on acquiring Senn Chemicals (~INR2b), GRAN would be further investing to integrate and scale up capacities/capabilities in the CDMO segment.

- The company submitted one ANDA in the oncology segment, and there are about 10 products under development.
- The paracetamol API business remains considerably impacted due to adverse supply-demand scenarios.

### Quarterly Performance

(INR m)

Y/E March (Consolidated)	FY24				FY25				FY24	FY25E	FY25E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	vs Est
<b>Net Sales</b>	<b>9,855</b>	<b>11,895</b>	<b>11,556</b>	<b>11,758</b>	<b>11,799</b>	<b>9,666</b>	<b>11,377</b>	<b>11,974</b>	<b>45,063</b>	<b>44,816</b>	<b>11,322</b>	<b>5.8</b>
YoY Change (%)	-3.3	3.4	0.8	-1.6	19.7	-18.7	-1.5	1.8	-0.1	-0.5	-3.7	
Total Expenditure	8,276	9,765	9,051	9,201	9,206	7,633	9,074	9,451	36,293	35,364	8,799	
<b>EBITDA</b>	<b>1,579</b>	<b>2,130</b>	<b>2,505</b>	<b>2,557</b>	<b>2,593</b>	<b>2,033</b>	<b>2,303</b>	<b>2,524</b>	<b>8,770</b>	<b>9,452</b>	<b>2,523</b>	<b>0.0</b>
YoY Change (%)	-25.4	-12.3	8.3	8.3	64.2	-4.5	-8.1	-1.3	-4.9	7.8	-1.3	
Margins (%)	16.0	17.9	21.7	21.7	22.0	21.0	20.2	21.1	19.5	21.1	22.3	
Depreciation	492	525	524	532	529	525	566	635	2,073	2,255	567	
<b>EBIT</b>	<b>1,086</b>	<b>1,605</b>	<b>1,981</b>	<b>2,025</b>	<b>2,064</b>	<b>1,508</b>	<b>1,737</b>	<b>1,889</b>	<b>6,697</b>	<b>7,197</b>	<b>1,956</b>	<b>-3.4</b>
YoY Change (%)	-35.4	-19.3	8.3	8.1	90.0	-6.0	-12.3	-6.7	-9.2	7.5	-3.4	
Margins (%)	11.0	13.5	17.1	17.2	17.5	15.6	15.3	15.8	14.9	16.1	17.3	
Interest	225	260	286	288	270	257	266	240	1,058	1,032	228	
Other Income	3	15	7	19	21	32	57	19	44	129	1	
<b>PBT before EO expense</b>	<b>865</b>	<b>1,360</b>	<b>1,701</b>	<b>1,756</b>	<b>1,814</b>	<b>1,284</b>	<b>1,528</b>	<b>1,668</b>	<b>5,683</b>	<b>6,294</b>	<b>1,729</b>	<b>-3.5</b>
Extra-Ord expense	211	0	0	0	0	0	0	-308	211	-308	0	
<b>PBT</b>	<b>654</b>	<b>1,360</b>	<b>1,701</b>	<b>1,756</b>	<b>1,814</b>	<b>1,284</b>	<b>1,528</b>	<b>1,976</b>	<b>5,472</b>	<b>6,001</b>	<b>1,729</b>	
Tax	176	339	444	460	468	311	352	455	1,419	1,587	489	
Rate (%)	26.9	24.9	26.1	26.2	25.8	24.3	23.0	23.0	25.9	24.0	28.3	
(Profit)/Loss of JV/Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0	
<b>Reported PAT</b>	<b>479</b>	<b>1,021</b>	<b>1,257</b>	<b>1,296</b>	<b>1,346</b>	<b>972</b>	<b>1,176</b>	<b>1,520</b>	<b>4,052</b>	<b>5,015</b>	<b>1,240</b>	<b>22.6</b>
<b>Adjusted PAT</b>	<b>633</b>	<b>1,021</b>	<b>1,257</b>	<b>1,296</b>	<b>1,346</b>	<b>972</b>	<b>1,176</b>	<b>1,284</b>	<b>4,207</b>	<b>4,778</b>	<b>1,240</b>	<b>3.5</b>
YoY Change (%)	-50.4	-29.6	1.1	3.4	112.7	-4.8	-6.4	-1.0	-19.5	13.6	-4.4	
Margins (%)	6.4	8.6	10.9	11.0	11.4	10.1	10.3	10.7	9.3	10.7	11.0	
<b>EPS</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>5</b>	<b>6</b>	<b>4</b>	<b>5</b>	<b>5</b>	<b>17</b>	<b>20</b>	<b>5</b>	<b>3.5</b>

E: MOFSL Estimates

### Key performance Indicators (Consolidated)

Y/E March	FY24				FY25				FY24	FY25E	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE
<b>FD</b>	<b>5,420</b>	<b>7,375</b>	<b>7,627</b>	<b>8,642</b>	<b>8,912</b>	<b>7,490</b>	<b>8,674</b>	<b>9,259</b>	<b>29,090</b>	<b>34,335</b>	<b>8,678</b>
YoY Change (%)	-1.2	25.9	45.9	41.3	64.4	1.6	13.7	7.1	28.2	18.0	0.4
<b>PFI</b>	<b>1,478</b>	<b>1,427</b>	<b>1,733</b>	<b>1,482</b>	<b>997</b>	<b>756</b>	<b>1,309</b>	<b>1,232</b>	<b>6,107</b>	<b>4,294</b>	<b>1,213</b>
YoY Change (%)	-37.6	-39.2	-18.7	-31.8	-32.6	-47.0	-24.5	-16.9	-32.3	-29.7	-18.2
<b>API</b>	<b>2,957</b>	<b>2,974</b>	<b>2,196</b>	<b>1,633</b>	<b>1,890</b>	<b>1,420</b>	<b>1,393</b>	<b>1,483</b>	<b>9,823</b>	<b>6,186</b>	<b>1,431</b>
YoY Change (%)	26.3	-10.0	-46.5	-55.5	-36.1	-52.2	-36.6	-9.2	-26.8	-37.0	-12.4
<b>Cost Break-up</b>											
RM Cost (% of Sales)	48.6	48.3	43.0	39.9	41.1	38.0	38.3	36.6	55.1	61.5	38.4
Staff Cost (% of Sales)	14.2	12.5	13.6	12.9	13.9	16.5	14.7	14.1	13.3	14.7	14.4
Other Cost (% of Sales)	21.1	21.2	21.7	25.4	23.1	24.5	26.7	28.2	22.4	25.7	24.9
Gross Margin (%)	51.4	51.7	57.0	60.1	58.9	62.0	61.7	63.4	44.9	38.5	61.6
EBITDA Margin (%)	16.0	17.9	21.7	21.7	22.0	21.0	20.2	21.1	19.5	21.1	22.3
EBIT Margin (%)	11.0	13.5	17.1	17.2	17.5	15.6	15.3	15.8	14.9	16.1	17.3

E: MOFSL Estimates




## Conference call highlights

- GRAN incurred remediation costs to the tune of INR600m in FY25. GRAN would incur such costs in 1HFY26 as well. However, the quantum is expected to reduce over the medium term.
- The EU business has been severely impacted by the weakness in the Paracetamol business. Having said this, GRAN intends to increase the pace of filings to revive growth in this segment.
- Meaningful revenue from the Oncology segment is expected from FY28.
- GRAN filed three ANDAs in 4QFY25. It has about 127 products filed/92 approved across its focus markets.
- R&D spending was INR2.3b in FY25 (vs. INR2b in FY24).


## Key exhibits

**Exhibit 1: Revenue grew 2% YoY in 4QFY25**



Source: MOFSL, Company

**Exhibit 2: EBITDA margin contracted 70bp YoY in 4QFY25**



Source: MOFSL, Company

## Capacity-led FDF expansion and entry of peptide CDMO to anchor the next growth phase

### Building product pipeline/adding capacity to drive growth in the FDF segment

- In FY25, overall sales were stable YoY at INR44.8b, as the 18% rise in FDF sales was offset by a decline in API and PFI sales. The API/PFI sales were hit by price erosion, demand issues, and production slowdowns following the USFDA-related remediation at the Gagilapur facility.
- GRAN commenced operations of an additional 7.5b dosage line at its Genome Valley facility in 4QFY25, enabling the launch of complex products in the EU and other international markets.
- GRAN has increased its FDF capacity by 34% in FY25 to 39.4b tablets. Interestingly, management has expanded capacity in the FDF segment only in FY25, indicating the strategic focus towards higher-margin formulations.
- Further, the shift in revenue mix reinforces this trend. The FD to API+PFI revenue split has evolved from 50:50 in FY23 to 65:35 in FY24 and further to 77:23 in FY25. This declining contribution from API and PFI segments reflects both market challenges and a deliberate shift in management's strategic priorities, supporting the limited investment in API and PFI capacity expansion.
- GRAN's acquisition of Senn Chemicals AG marks its strategic entry into the high-growth peptide therapeutics and CDMO space. Leveraging Senn's expertise in

peptide synthesis and strong European presence, it aims to expand into complex therapies like GLP-1 agonists, strengthen its global innovation footprint, and become a key player in peptide-based pharmaceuticals, cosmetics, and theragnostic segments.


### Enhancing prospects in regulated markets (US/EU)

- In FY25, GRAN reported 16% YoY growth in the US to INR34.5b, largely due to new launches in the Rx and OTC businesses. This was partly offset by the voluntary shutdown of the Gagillapur plant. Europe revenue declined 50% YoY to INR4.4b due to price erosion in paracetamol.
- GRAN has launched new products, such as Metoprolol, Kcl-tabs & Caps, Gabapentin, and Sertraline, which will drive growth in the US business.
- GRAN plans to file complex products in the Rx and OTC markets in the US, supported by the recent launches in new dosage forms.
- GRAN is implementing efforts to FDF-led growth in Europe through key partnerships and Dossier Sales/ BD deals on existing and new products.
- The management expects to launch a couple of complex products in the regulated market in the near term, which would support GRAN's overall growth.

### Reiterate BUY


- We cut our earnings estimates by 8%/6% for FY26/FY27 factoring in 1) an extended production disruption at the Gagillapur site to implement remediation measures, 2) additional operational costs related to Senn Chemicals, and 3) a weak pricing in Paracetamol API. We value GRAN at 18x 12M forward earnings to arrive at our TP of INR600.
- GRAN is focusing on building a differentiated product pipeline in the oncology and ADHD domains. With the Senn Chemicals acquisition, it is adding peptide CDMO as a growth driver for the future. It is also adding capacities in the FDF segment to cater to future manufacturing requirements. Overall, we expect a 14%/20%/26% revenue/EBITDA/PAT CAGR during FY25-27. **Reiterate BUY.**

**Exhibit 3: P/E chart**



Source: MOFSL, Company, Bloomberg


**Exhibit 4: EV/EBITDA chart**




Source: MOFSL, Company, Bloomberg

## Story in charts


**Exhibit 5: Expect a revenue CAGR of 15% over FY25-27**




**Exhibit 6: EBITDA margin to expand 160bp over FY25-27**




**Exhibit 7: FD to further increase to 78% in FY26**




**Exhibit 8: FDF sales to clock 21% CAGR over FY25-27**



**Exhibit 9: PAT to exhibit a 26% CAGR over FY25-27**



**Exhibit 10: Return ratios rising steadily over FY24-26**



## Financials and valuations

### Consolidated - Income Statement

	INRm								
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Total Income from Operations</b>	<b>22,792</b>	<b>25,986</b>	<b>32,375</b>	<b>37,477</b>	<b>45,119</b>	<b>45,063</b>	<b>44,816</b>	<b>50,581</b>	<b>58,747</b>
Change (%)	34.7	14.0	24.6	15.8	20.4	-0.1	-0.5	12.9	16.1
<b>Total Expenditure</b>	<b>18,872</b>	<b>20,513</b>	<b>23,665</b>	<b>30,427</b>	<b>35,901</b>	<b>36,293</b>	<b>35,364</b>	<b>39,302</b>	<b>45,235</b>
% of Sales	82.8	78.9	73.1	81.2	79.6	80.5	78.9	77.7	77.0
<b>EBITDA</b>	<b>3,920</b>	<b>5,473</b>	<b>8,710</b>	<b>7,050</b>	<b>9,218</b>	<b>8,770</b>	<b>9,452</b>	<b>11,280</b>	<b>13,512</b>
Margin (%)	17.2	21.1	26.9	18.8	20.4	19.5	21.1	22.3	23.0
Depreciation	1,055	1,370	1,515	1,586	1,845	2,073	2,255	2,603	2,772
<b>EBIT</b>	<b>2,866</b>	<b>4,104</b>	<b>7,195</b>	<b>5,464</b>	<b>7,373</b>	<b>6,697</b>	<b>7,197</b>	<b>8,677</b>	<b>10,740</b>
Int. and Finance Charges	285	270	263	232	559	1,058	1,032	1,132	1,000
Other Income	267	366	152	176	138	44	129	126	147
<b>PBT bef. EO Exp.</b>	<b>2,848</b>	<b>4,199</b>	<b>7,085</b>	<b>5,407</b>	<b>6,952</b>	<b>5,683</b>	<b>6,294</b>	<b>7,671</b>	<b>9,886</b>
EO Items	-80	57	-40	173	-80	-211	308	0	0
<b>PBT after EO Exp.</b>	<b>2,768</b>	<b>4,257</b>	<b>7,045</b>	<b>5,580</b>	<b>6,872</b>	<b>5,472</b>	<b>6,601</b>	<b>7,671</b>	<b>9,886</b>
Current Tax	891	1,257	1,954	1,382	1,772	1,652	1,828	1,780	2,294
Deferred Tax	72	-100	-405	70	-66	-233	-242	0	0
Tax Rate (%)	34.8	27.2	22.0	26.0	24.8	25.9	24.0	23.2	23.2
Add: Associate income	487	255	0	0	0	0	0	0	0
<b>Reported PAT</b>	<b>2,292</b>	<b>3,354</b>	<b>5,496</b>	<b>4,128</b>	<b>5,166</b>	<b>4,052</b>	<b>5,015</b>	<b>5,892</b>	<b>7,593</b>
<b>Adjusted PAT</b>	<b>2,345</b>	<b>3,313</b>	<b>5,524</b>	<b>4,000</b>	<b>5,224</b>	<b>4,207</b>	<b>4,778</b>	<b>5,892</b>	<b>7,593</b>
Change (%)	76.8	41.3	66.8	-27.6	30.6	-19.5	13.6	23.3	28.9
Margin (%)	10.2	12.6	17.0	10.6	11.5	9.3	10.6	11.6	12.9

### Consolidated - Balance Sheet

	INRm								
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	254	254	248	248	242	242	243	243	243
Total Reserves	15,040	18,183	21,485	25,617	28,107	32,013	36,913	42,521	49,830
<b>Net Worth</b>	<b>15,295</b>	<b>18,437</b>	<b>21,733</b>	<b>25,865</b>	<b>28,349</b>	<b>32,255</b>	<b>37,156</b>	<b>42,764</b>	<b>50,073</b>
Minority Interest	0	0	0	6	0	0	0	0	0
Deferred Liabilities	655	482	11	139	77	231	314	314	314
Total Loans	9,330	7,932	7,504	10,928	11,362	13,151	14,548	13,752	12,922
<b>Capital Employed</b>	<b>25,279</b>	<b>26,851</b>	<b>29,248</b>	<b>36,938</b>	<b>39,788</b>	<b>45,637</b>	<b>52,017</b>	<b>56,829</b>	<b>63,308</b>
Gross Block	16,639	21,442	22,220	25,355	30,897	34,817	40,381	46,381	50,881
Less: Accum. Deprn.	5,473	6,842	8,357	9,943	11,788	13,861	16,116	18,719	21,491
<b>Net Fixed Assets</b>	<b>11,167</b>	<b>14,600</b>	<b>13,863</b>	<b>15,412</b>	<b>19,109</b>	<b>20,956</b>	<b>24,265</b>	<b>27,662</b>	<b>29,390</b>
Capital WIP	3,235	1,481	1,848	3,562	2,394	2,717	4,402	5,058	4,700
<b>Total Investments</b>	<b>2,104</b>	<b>193</b>	<b>190</b>	<b>197</b>	<b>361</b>	<b>382</b>	<b>426</b>	<b>426</b>	<b>426</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>13,279</b>	<b>15,957</b>	<b>21,226</b>	<b>25,945</b>	<b>27,168</b>	<b>30,783</b>	<b>32,755</b>	<b>34,632</b>	<b>39,950</b>
Inventory	3,842	4,384	7,822	9,786	11,494	13,005	13,428	14,752	16,731
Account Receivables	6,735	6,620	7,654	9,250	9,485	9,858	9,422	11,225	14,003
Cash and Bank Balance	890	2,839	2,710	4,095	3,128	3,864	5,964	4,207	3,342
Loans and Advances	1,811	2,113	3,040	2,815	3,060	4,056	3,941	4,448	5,875
<b>Curr. Liability &amp; Prov.</b>	<b>4,548</b>	<b>5,432</b>	<b>7,887</b>	<b>8,191</b>	<b>9,258</b>	<b>9,573</b>	<b>10,509</b>	<b>11,627</b>	<b>11,835</b>
Account Payables	3,235	3,569	5,410	6,386	7,821	7,495	7,261	8,291	9,667
Other Current Liabilities	1,144	1,589	2,160	1,294	998	1,580	2,614	2,950	1,762
Provisions	169	275	317	511	439	497	634	386	406
<b>Net Current Assets</b>	<b>8,731</b>	<b>10,525</b>	<b>13,340</b>	<b>17,753</b>	<b>17,910</b>	<b>21,211</b>	<b>22,247</b>	<b>23,005</b>	<b>28,114</b>
<b>Appl. of Funds</b>	<b>25,279</b>	<b>26,852</b>	<b>29,248</b>	<b>36,938</b>	<b>39,788</b>	<b>45,637</b>	<b>52,017</b>	<b>56,829</b>	<b>63,308</b>



## Financials and valuations

### Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>EPS</b>	<b>9.7</b>	<b>13.7</b>	<b>22.8</b>	<b>16.5</b>	<b>21.5</b>	<b>17.3</b>	<b>19.7</b>	<b>24.3</b>	<b>31.3</b>
Cash EPS	13.4	18.4	28.4	22.5	29.2	25.9	29.0	35.0	42.7
BV/Share	60.2	72.5	87.7	104.3	117.1	133.1	153.2	176.3	206.5
DPS	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Payout (%)	13.4	8.9	5.3	7.0	5.5	7.0	5.7	4.8	3.7
<b>Valuation (x)</b>									
P/E	60.0	42.5	25.5	35.2	26.9	33.4	29.4	23.9	18.5
Cash P/E	43.4	31.5	20.4	25.7	19.9	22.4	20.0	16.6	13.6
P/BV	9.6	8.0	6.6	5.6	5.0	4.4	3.8	3.3	2.8
EV/Sales	7.6	6.6	5.3	4.6	3.9	3.9	3.9	3.5	3.0
EV/EBITDA	44.4	31.2	19.6	24.5	18.9	20.0	18.4	15.5	13.0
Dividend Yield (%)	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
<b>Return Ratios (%)</b>									
RoE	16.5	19.6	27.5	16.8	19.3	13.9	13.8	14.7	16.4
RoCE	8.6	12.8	20.6	12.6	14.8	11.7	11.5	12.5	14.0
RoIC	10.2	14.4	24.0	15.1	17.6	13.7	13.7	15.1	16.2
<b>Working Capital Ratios</b>									
Asset Turnover (x)	0.9	1.0	1.1	1.0	1.1	1.0	0.9	0.9	0.9
Inventory (Days)	53	58	69	86	86	99	108	102	98
Debtor (Days)	103	94	80	82	76	78	79	74	78
Creditor (Days)	56	61	69	71	72	77	76	72	72
<b>Leverage Ratio (x)</b>									
Current Ratio	2.9	2.9	2.7	3.2	2.9	3.2	3.1	3.0	3.4
Interest Cover Ratio	10	15	27	24	13	6	7	8	11
Debt/Equity	0.6	0.4	0.3	0.4	0.4	0.4	0.4	0.3	0.3

### Consolidated - Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	2,848	4,256	7,044	5,580	6,952	5,472	6,294	7,671	9,886
Depreciation	1,055	1,370	1,515	1,586	1,845	2,073	2,255	2,603	2,772
Interest & Finance Charges	18	207	139	232	559	1,058	903	1,006	853
Direct Taxes Paid	-891	-1,191	-1,914	-1,450	-1,758	-1,903	-1,587	-1,780	-2,294
(Inc)/Dec in WC	-377	128	-2,749	-2,572	-103	-2,463	1,064	-2,515	-5,975
<b>CF from Operations</b>	<b>2,652</b>	<b>4,769</b>	<b>4,034</b>	<b>3,376</b>	<b>7,495</b>	<b>4,238</b>	<b>8,930</b>	<b>6,985</b>	<b>5,243</b>
Others	0	-7	291	-56	-27	156	0	0	0
<b>CF from Operating incl EO</b>	<b>2,652</b>	<b>4,762</b>	<b>4,325</b>	<b>3,321</b>	<b>7,467</b>	<b>4,394</b>	<b>8,930</b>	<b>6,985</b>	<b>5,243</b>
(inc)/dec in FA	-2,544	-1,843	-2,710	-3,967	-4,107	-3,788	-7,248	-6,656	-4,142
(Pur)/Sale of Investments	-539	0	-2	0	2,035	159	-43	0	0
Others	267	237	-59	166	158	28	129	126	147
<b>CF from Investments</b>	<b>-2,816</b>	<b>-1,606</b>	<b>-2,771</b>	<b>-3,801</b>	<b>-1,914</b>	<b>-3,602</b>	<b>-7,163</b>	<b>-6,530</b>	<b>-3,995</b>
Issue of Shares	195	0	41	37	-3,084	32	169	0	0
(Inc)/Dec in Debt	-252	-1,534	-719	2,530	-600	1,435	1,397	-796	-830
Interest Paid	-285	-266	-263	-242	-533	-1,027	-1,032	-1,132	-1,000
Dividend Paid	-306	-307	-247	-372	-186	-363	-284	-284	-284
<b>CF from Fin. Activity</b>	<b>-102</b>	<b>-2,129</b>	<b>-2,993</b>	<b>1,900</b>	<b>-4,403</b>	<b>77</b>	<b>333</b>	<b>-2,212</b>	<b>-2,114</b>
<b>Inc/Dec of Cash</b>	<b>-266</b>	<b>1,027</b>	<b>-1,440</b>	<b>1,419</b>	<b>1,151</b>	<b>869</b>	<b>2,100</b>	<b>-1,757</b>	<b>-866</b>
Opening Balance	1,156	890	2,839	2,711	4,095	3,128	3,863	5,964	4,207
FX	-30	921	1,312	-35	-2,118	-134	0	0	0
<b>Closing Balance</b>	<b>891</b>	<b>2,839</b>	<b>2,711</b>	<b>4,095</b>	<b>3,128</b>	<b>3,863</b>	<b>5,964</b>	<b>4,207</b>	<b>3,342</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## NOTES



Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

\*\*\*\*\*

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj

Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.